Clinical development of Puldysa®
(idebenone)
Kristina Sjöblom Nygren, MD – Chief Medical Officer

PPMD meeting Orlando | June 28, 2019
Disclaimer

This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities issued by Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG makes no representation (either express or implied) that the information and opinions expressed in this presentation are accurate, complete or up to date. Santhera Pharmaceuticals Holding AG disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this presentation.

This presentation expressly or implicitly contains certain forward-looking statements concerning Santhera Pharmaceuticals Holding AG and its business. Certain of these forward-looking statements can be identified by the use of forward-looking terminology or by discussions of strategy, plans or intentions. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Santhera Pharmaceuticals Holding AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that any of the research and/or development projects described will succeed or that any new products or indications will be brought to market. Similarly, there can be no guarantee that Santhera Pharmaceuticals Holding AG or any future product or indication will achieve any particular level of revenue.

In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products, including unexpected preclinical and clinical trial results; unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Santhera Pharmaceuticals Holding AG is providing the information in this new release as of the date of the publication, and does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Understanding respiratory function in DMD
Medical need for effective treatment of respiratory illness in non-ambulatory patients with DMD

• Increasing respiratory muscle weakness in DMD leads to:
  – Decreased lung volumes and air flow
  – Decreased ability to cough effectively and clear airways of mucus
  – Increased risk of airway infections/pneumonias

• There are no approved pharmacological therapies for treating respiratory decline

Progressive respiratory function loss results in need of assisted ventilation
Respiratory function follows a linear decline over time

[Graph showing the decline of FVC% and PEF% over age]

Data are mean ± SEM of pulmonary function tests (PFT) from 334 patients of the CINRG-DNHS; Dotted lines at ages 10 and 20 years: period of approximately linear decline in PEF%p and FVC%p. Mayer OH, et al. US Neurology 2017;13:35–41. McDonald et al. Neuromuscular Disorders 2018; 28: 897-909
Glucocorticoids delay the onset of respiratory function decline by 2-3 years but not the annual rate of decline.

Data is mean ± SEM (n=334); GC= glucocorticoid
Red arrows indicate shift in start of pulmonary function decline by GC use of about 2–3 years.
Clinical development of Puldysa® (idebenone) as treatment of respiratory dysfunction
Overview of clinical development of idebenone in DMD

Idebenone is an investigational compound in the US and is not approved by the FDA.
DELOS: Completed Phase 3 study

Objective: To study how effective idebenone is compared to placebo on treating respiratory dysfunction in patients with DMD not on glucocorticoid steroids

DELOS: Placebo-controlled study in patients with DMD age 10 and older

Study details

64 males with DMD 92% of patients were no longer walking 17 centers in Europe and USA 52 weeks Idebenone or placebo
Data from placebo-controlled DELOS study showed that idebenone slowed loss of respiratory function over 12 months

- **Idebenone** slowed loss of expiratory respiratory function (peak expiratory flow, PEF%p) and met the study primary endpoint. 1,2

- Consistent treatment effects were seen for inspiratory function (inspiratory flow reserve, IFR) and global respiratory function (forced vital capacity, FVC%p) 1,3, 4,*

- **Idebenone** also reduced the risk of bronchopulmonary adverse events (such as airway infections), the need of systemic antibiotic treatment and risk of hospitalization due to respiratory complications 5,*

---

1) Buyse et al. 2015; Lancet 385:1748-57;
2) Buyse et al. 2018; J Neuromuscular Diseases 5: 419–430;
3) Mayer et al. 2017; J Neuromuscular Diseases. 4:189-98;
4) Buyse et al., 2017; Pediatric Pulmonology 52:508-515;
5) McDonald et al., 2016; Neuromuscular Disorders 26: 473–480

* These statements have not been evaluated by any health regulatory agency including the FDA

PEF%p: peak expiratory flow percent predicted
FVC%p: forced vital capacity percent predicted
Rate of change of PEF%p and FVC%p predicts time to clinically relevant milestone

Time from crossing 50% of PEF%p (left) and FVC%p (right) to **initiation of assisted ventilation** (CINRG study)

Annual decline slower than average (blue line) prolongs the time from crossing 50% to assisted ventilation by ~3 years compared with progression more rapid than average (red line)

Source: McDonald et al (Poster presentation at MDA Conference 2019)
SYROS: New long-term efficacy data with idebenone on respiratory function outcomes – the real world approach

- Long-term efficacy data are desirable to inform about potential patient benefit in this chronic disease
- **SYROS**: prospectively planned collection of long-term respiratory function data from patients previously enrolled in the DELOS trial
- Long-term respiratory function data were collected from 18 patients treated with idebenone in Expanded Access Programs (EAPs) in Europe
SYROS: Idebenone treatment showed persistent effect on respiratory function for up to 6 years

- **Idebenone** treatment showed a persistent effect in slowing decline in FVC%p for up to 6 years*

- Annual decline in FVC%p in patients on idebenone was consistently smaller than in untreated patients from a matched external control group (from CINRG Duchenne natural history study)

Mayer et al. 2019; Poster presented at MDA Clinical and Scientific Conference; April 2019

* These statements have not been evaluated by any health regulatory agency including the FDA
SYROS: Frequency of Bronchopulmonary Adverse Events (BAEs)

- Data show a reduced risk for BAEs during idebenone treatment periods
- Similar results as in DELOS study (McDonald et al., 2016)

Kaplan-Meier analysis (proportional means regression model) for cumulative frequency of BAEs by treatment. N=14 patients for Off-Idebenone periods; N=18 patients for On-Idebenone periods.

Mayer et al. 2019; Poster presented at MDA Clinical and Scientific Conference; April 2019
SIDEROS study: To test the efficacy of idebenone in patients on glucocorticoid treatment

Recruiting now
SIDEROS: Ongoing Phase 3 study

- Currently the largest ongoing clinical trial in DMD (266 males)
- Enrollment expected to complete in next few months
- Ambulant and non-ambulant patients eligible for enrolment
- Patients of all mutation types eligible. Additional eligibility criteria apply
- Participants who complete SIDEROS and are considered eligible by their investigator are offered to participate in open-label SIDEROS Extension trial

www.siderosdmd.com
SIDEROS Objective: To evaluate the efficacy of idebenone to slow respiratory function decline in patients using glucocorticoids (GCs)

**Study type:** Randomized, placebo-controlled trial

**Key eligibility criteria:** ≥ 10 years, chronic use of systemic glucocorticoids and in respiratory function decline

**Primary endpoint:** Change in FVC%p from baseline to week 78

**Secondary endpoints:** Changes in PEF%p, time to loss of 10% in FVC, inspiratory flow reserve, others
SIDEROS: key inclusion criteria

- Patients ≥ 10 years old at Screening (no upper age limit)
- Patients with all types of DMD mutations eligible
- Willing and able to provide consent
- FVC between 80% and 35% at start of study
- Reliable FVC values at screening and baseline (within defined margin)
- Chronic use of systemic glucocorticoid steroids for DMD for at least 12 months
- Immunization: pneumococcal vaccine, inactivated influenza vaccine
SIDEROS: clinical trial sites in the US and Europe

Approximately 60 study centers in USA, Europe and Israel

For updated information, please visit: www.siderosdmd.com
### SIDEROS and regulatory plans for Puldysa® in DMD

**United States**

- Top-line SIDEROS data available 1H 2021
- Positive SIDEROS study allows for submission to FDA in US
- Plan to apply for full approval for all boys with DMD regardless of steroid use

**Europe**

- Successful Phase 3 DELOS study is basis for regulatory submission in Europe (May 2019)
  - Additional natural history data support clinical importance of treatment effect
  - Open-label real world SYROS-study support long-term effect
- Conditional Marketing Authorization for boys not using steroids
- SIDEROS-data: Plan to investigate expanded indication for boys using steroids
Summary

- Treating respiratory function decline is an urgent unmet medical need
- The DELOS-study reported statistically significant effect of Puldysa® (idebenone) on slowing the decline of respiratory function
- Real-world long-term data (SYROS) has reported effect on respiratory function up to 6 years of treatment
- Natural history data show clinical relevance of slowing decline of respiratory function in DMD
- Enrollment into Phase 3 SIDEROS trial expected to complete this fall
- SIDEROS outcome will be important for both US and EU regulatory submissions
Thank you

We would like to sincerely thank the patients and their carers for their trust and efforts to participate in clinical trials.

Your support enables us all to learn more about how therapies could be developed in the hope to benefit all patients.